Protox Therapeutics Retains Leading Investor Relations Firm
Friday, June 23, 2006 - Vancouver, British Columbia - Protox Therapeutics Inc. (TSX-V: PRX) today announced that it has retained The Equicom Group Inc. to provide the Company with strategic investor relations and financial communications services.
“We're extremely pleased to have partnered with the Equicom Group for our investor relations and corporate communications efforts,” said Dr. Fahar Merchant, President and Chief Executive Officer of Protox Therapeutics. “In view of the company's anticipated progress and growth, we are confident this relationship will help us effectively build our profile and convey our key messages to the investment community outside our core investor base in British Columbia.”
Equicom provides strategic communications services to more than 80 Canadian public companies across a diverse range of industries, including over 35 life science companies. Protox will pay Equicom a monthly retainer fee of $6,500 for select services. The initial contract term is for 12 months. Equicom does not have an ownership interest, directly or indirectly, in Protox or its securities. Equicom is an employee owned firm whose principals include Barry Hildred, President and Jason Hogan, Executive Vice President.
About Protox Therapeutics:
Protox Therapeutics is a product-focused development-stage company and a leader in advancing novel, targeted protein toxin therapeutics for treatment of cancer and other diseases. Through the Company's PORxin™ technology platform, therapeutic candidates are generated by engineering the naturally occurring protein, proaerolysin. The resulting therapeutic candidates are inactive pro-drugs that are preferentially activated at the target site into potent pore-forming proteins by cancer or disease specific proteases, thereby causing cell death. The Company's lead compound, PRX302, is in Phase I clinical trials for the treatment of localized prostate cancer. PRX302 is also being developed for the treatment of benign prostatic hyperplasia.
For more information, contact:
Elayne Wandler
Director, Investor Relations and Corporate Communications, Protox Therapeutics Inc.
Direct: 604-688-4369
Cell: 778-865-0172
Fax: 604-688-0173
ewandler@protoxtherapeutics.com
or:
Michael Moore Investor Relations
Direct: 416-815-0700 x 241
mmoore@equicomgroup.com
